Prices verified May 2026, confirm the current price with the provider
NAD+ BENEFITS Selective NNMT inhibition substrate-site targeting with minimal off-target activity in preclinical models NAD+ salvage modulation studied for increasing intracellular NAD+ and SAM availability Adipose metabolism investigated for suppression of adipocyte lipogenesis in 3T3-L1 models Small molecule distinct mechanism from peptide-based metabolic compounds (GLP-1 agonists, etc.) Defined pharmacology IC of 1.2 M confirmed in published enzymatic assays WHAT RESEARCHERS LOOK AT NNMT enzyme inhibition kinetics and SAM/1-MNA substrate balance NAD+ and SAM level changes in adipocyte and hepatocyte cell models Lipogenesis suppression in 3T3-L1 differentiated adipocyte assays Polyamine flux enzyme upregulation (ODC, SSAT) and histone methylation In vivo efficacy in diet-induced obesity (DIO) murine models
[DOI] [PubMed] [Google Scholar] 450.Pandey A, et al
Ingredients: Vitamin B1 50,000 mcg/mL (Thiamine) and B12 100mcg of methylcobalamin
Our findings suggest that GLP-1R/GCGR dual-agonists provide benefits to patients with obesity, T2D and MASH and can likely be quite effective in preventing T2D progression in patients with prediabetes, especially if also exhibiting hepatic steatosis
Figure 1 The occurrence of COVID-19 with thrombotic events has been shown to have a higher rate of hospitalization and an incidence of ARDS (49) and is independently associated with the risk of death ( Dipeptidyl peptidase 4 Dipeptidyl peptidase 4 (DPP4), also known as CD26, is widely distributed in the kidney, usually present in membrane-bound and soluble forms, involved in the degradation of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1), thus interfering with insulin secretion and disrupting glucose homeostasis (50)
